Neurology News and Research

Latest Neurology News and Research

Encorium Group reports 21.4% decrease in fourth-quarter net revenue

Encorium Group, Inc., a full service multinational clinical research organization conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced its financial results for the fourth quarter and year ended December 31, 2009.

20 Apr 2010

FTO gene associated with loss of brain tissue: UCLA researchers

Three years ago, geneticists reported the startling discovery that nearly half of all people in the U.S. with European ancestry carry a variant of the fat mass and obesity associated gene, which causes them to gain weight - from three to seven pounds, on average - but worse, puts them at risk for obesity.

20 Apr 2010

Caliper Life Sciences introduces Quantum FX stand-alone microCT system for preclinical imaging

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery, life sciences research and molecular diagnostics, today announced the Quantum FX, a stand-alone microCT system for preclinical imaging. Introduced at the American Association for Cancer Research Annual Meeting 2010, the Quantum FX is a low dose, microCT system that provides researchers with a 3-dimensional anatomical view of disease activity, tumor development and therapeutic response over multiple time points during the course of a study.

19 Apr 2010

New p53 knockout rat model improves timelines for carcinogenicity screening

Sigma Life Science, the innovative biological products and services brand of Sigma-Aldrich, today introduced the world's first p53 'knockout' rat model, an important development that is expected to, due to the rat's closer physiological and metabolic similarity to humans, significantly improve timelines for carcinogenicity screening and reduce time to market for therapeutics.

19 Apr 2010

Study shows ultrathin flexible implants can effectively record brain activity

Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.

19 Apr 2010

President of Tanzania emphasizes on health care in Global Health Grand Rounds lecture

President Jakaya Kikwete of the United Republic of Tanzania spoke at Weill Cornell Medical College today. In his Global Health Grand Rounds lecture, President Kikwete discussed the most significant challenges facing Tanzania, with a particular focus on health care and the advances made during his first term.

17 Apr 2010

Access to NAbs testing important for MS therapy management

Teva Neuroscience today announced results at the 62nd American Academy of Neurology Annual Meeting which demonstrated that eliminating barriers to neutralizing antibodies (NAbs) testing significantly impacted multiple sclerosis (MS) treatment choices in patients receiving interferon beta (IFNβ) therapies.

17 Apr 2010

Australian study uncovers mechanisms involved in the progression of Alzheimer's disease

A major Australian study has provided new insights into the loss of structure in regions of the brain and its potential association with Alzheimer's Disease. The findings recently reported in Neurology suggest a build-up of deposits of the protein amyloid-beta in a region of the brain known as the temporal inferior cortex.

17 Apr 2010

Study shows beneficial impact of TYSABRI on QoL in MS patients

Biogen Idec and Elan Corporation, plc today announced results from a one-year, longitudinal health outcomes studys 62nd Annual Meeting in Toronto, April 10 - 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists.

17 Apr 2010

Intensive rehabilitation therapy with robotic aids can help stroke patients regain limb movement

Patients show modest yet meaningful gains in limb movement and an improved outlook on life years after suffering a stroke, a major clinical study has found. The paper, published online this week in the New England Journal of Medicine, provides the best evidence yet that stroke sufferers in a controlled study can regain limb movement long after an injury, through intensive therapy with specially trained personnel and newly created robotic aids.

17 Apr 2010

New data on Cladribine Tablets presented at AAN annual meeting

EMD Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that new data providing further understanding on Cladribine Tablets as a potential new therapeutic option for relapsing forms of multiple sclerosis were presented at the 62nd Annual Meeting of the American Academy of Neurology.

17 Apr 2010

Knopp Neurosciences to initiate Phase 3 studies of KNS-760704 in AL

In an invited presentation today before the annual meeting of the American Academy of Neurology, Knopp Neurosciences Inc. described further encouraging trends observed in a previously reported Phase 2 study of KNS-760704 (dexpramipexole) in ALS.

17 Apr 2010

Premature ejaculation causes intense distress on men and partners

Today, the first key findings from 'PE Confidential', a unique Europe-wide public survey on premature ejaculation (PE), reveal the intense - and in many cases - long years of silent suffering that PE poses on men and their partners. 'PE Confidential' also highlights the significant burden that PE places on couples' relationships and why men are reluctant to seek help, advice and solutions for the condition.

16 Apr 2010

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced results from several studies demonstrating that laquinimod, a novel, investigational once-daily oral immunomodulator for relapsing remitting multiple sclerosis (RRMS) may have neuroprotective properties in addition to its anti-inflammatory effects.

16 Apr 2010

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease. The data provide hypotheses for further investigation of this agent in anemia management in this patient population.

16 Apr 2010

Age-related declines in peripheral nerve function may be related to metabolic factors: Study

New research investigating neurological decline in a population of "super healthy" elderly subjects found that the decline in neurological function of the peripheral nervous system attributed to aging may be related to metabolic factors, such as blood sugar levels, even if these factors are within the normal range.

16 Apr 2010

AVANIR Pharmaceuticals presents Phase III trial data of Zenvia for PBA at AAN Annual Meeting

AVANIR Pharmaceuticals, Inc. today announced the presentation of detailed data, including safety and tolerability data from the open-label extension as well as cardiac safety data from the double-blind phase of the Phase III confirmatory STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect (PBA). The data were presented in two posters at the American Academy of Neurology (AAN) Annual Meeting in Toronto, Canada.

15 Apr 2010

Study: Atorvastatin may slow down MS progression

A UCSF-led study examining the impact of statins on the progression of multiple sclerosis found a lower incidence of new brain lesions in patients taking the cholesterol-lowering drug in the early stages of the disease as compared to a placebo.

15 Apr 2010

New investigational treatment may help prevent involuntary outbursts in MS and ALS patients

Pseudobulbar affect (PBA) is a neurologic condition of involuntary, sudden and frequent episodes of laughing or crying and is quite common in patients with underlying neurologic diseases or injuries, especially those with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).

15 Apr 2010

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genzyme Corporation today reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an estimated 71 percent of alemtuzumab treated patients remain free of clinically-active disease as much as three years after most patients received their last course of the investigational compound. The data were presented at the American Academy of Neurology annual meeting.

15 Apr 2010

Neurology News and Research

Latest Neurology News and Research

Encorium Group reports 21.4% decrease in fourth-quarter net revenue

FTO gene associated with loss of brain tissue: UCLA researchers

Caliper Life Sciences introduces Quantum FX stand-alone microCT system for preclinical imaging

New p53 knockout rat model improves timelines for carcinogenicity screening

Study shows ultrathin flexible implants can effectively record brain activity

President of Tanzania emphasizes on health care in Global Health Grand Rounds lecture

Access to NAbs testing important for MS therapy management

Australian study uncovers mechanisms involved in the progression of Alzheimer's disease

Study shows beneficial impact of TYSABRI on QoL in MS patients

Intensive rehabilitation therapy with robotic aids can help stroke patients regain limb movement

New data on Cladribine Tablets presented at AAN annual meeting

Knopp Neurosciences to initiate Phase 3 studies of KNS-760704 in AL

Premature ejaculation causes intense distress on men and partners

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Age-related declines in peripheral nerve function may be related to metabolic factors: Study

AVANIR Pharmaceuticals presents Phase III trial data of Zenvia for PBA at AAN Annual Meeting

Study: Atorvastatin may slow down MS progression

New investigational treatment may help prevent involuntary outbursts in MS and ALS patients

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Aneuro: Advancing Neuroscience Research eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Neurology News and Research

Latest Neurology News and Research

Aneuro: Advancing Neuroscience Research eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in